The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Akero Therapeutics Inc shares valued at $1,534,895 were sold by Cheng Andrew on Jul 10 ’25. At $51.16 per share, Cheng Andrew sold 30,000 shares. The insider’s holdings dropped to 520,757 shares worth approximately $28.29 million following the completion of this transaction.
Also, Rolph Timothy sold 12,500 shares, netting a total of over 638,661 in proceeds. Following the sale of shares at $51.09 each, the insider now holds 167,124 shares.
Before that, Timothy Rolph had added 56,250 shares to its account. In a trade valued at $2,916,563, the Officer bought Akero Therapeutics Inc shares for $51.85 each.
As published in a research note from BofA Securities on January 30, 2025, Akero Therapeutics Inc [AKRO] has been rated up from a Neutral to a Buy and the price target has been revised to $63 from $35. Analysts at H.C. Wainwright resumed the stock at ‘”a Buy”‘ outlook in a report released in late January. As of November 18, 2024, Citigroup has initiated its “Buy” rating for AKRO.
Analyzing AKRO Stock Performance
On last trading session,, Akero Therapeutics Inc [NASDAQ: AKRO] rose 1.36% to $54.33. The stock’s lowest price that day was $53.09, but it reached a high of $54.985 in the same session. During the last five days, there has been a surge of approximately 4.48%. Over the course of the year, Akero Therapeutics Inc shares have jumped approximately 97.92%.
Support And Resistance Levels for Akero Therapeutics Inc (AKRO)
RSI (Relative Strength Index) is 58.59 on the 14-day chart, showing neutral technical sentiment.
Is Akero Therapeutics Inc subject to short interest?
Stocks of Akero Therapeutics Inc saw a sharp rise in short interest on 2025-06-13 jumping by 1.45 million shares to 7.75 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 6.3 million shares. A jump of 18.76% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 3.84 of the overall float, the days-to-cover ratio (short ratio) jumped to 3.84.
Which companies own the most shares of Akero Therapeutics Inc (AKRO)?
In terms of Akero Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 45 in the next 12 months, down nearly -16.04% from the previous closing price of $53.6. Analysts anticipate Akero Therapeutics Inc stock to reach 56 by 2025, with the lowest price target being 38. In spite of this, 4 analysts ranked Akero Therapeutics Inc stock as Buy at the end of 2025. On September 19, 2023, Cantor Fitzgerald assigned a price target of “an Overweight” to the stock and initiated coverage with a $69.
